Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:STIM

Neuronetics Q3 2026 Earnings Date & Estimates

Neuronetics logo
$2.19 +0.09 (+4.03%)
As of 10:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Neuronetics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Neuronetics in Q3 2026

Neuronetics is expected to post earnings of -$0.08 per share on revenue of $40.43 million. In the same quarter a year earlier Neuronetics reported -$0.13 per share on revenue of $37.30 million. Neuronetics last reported on August 11, 2026, posting -$0.05 per share and beating the -$0.1230 consensus estimate. Neuronetics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.08
Expected Revenue
$40.43 million
Prior-Year EPS
-$0.13
Prior-Year Revenue
$37.30 million
Expected Revenue Growth
+8.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.0730)
Last Quarter Revenue
$41.57 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Neuronetics Q3 2026 Earnings FAQ

Neuronetics (NASDAQ:STIM) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Neuronetics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Neuronetics to post earnings of -$0.08 per share for Q3 2026.

The consensus revenue estimate for Neuronetics is $40.43 million for Q3 2026.

Neuronetics Earnings Headlines

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385514/0/en/neuronetics-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call.html
Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure
October 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954297-neuronetics-transforming-from-device-manufacturer-to-psychedelic-infrastructure
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
October 26 at 1:00 AM  |  American Alternative (Ad)
Harmony Biosciences Names Peter Anastasiou CEO Effective January 1, 2027; Reaffirms 2026 WAKIX Guidance
October 12, 2026  |  quiverquant.comQ
B Riley Securities initiates coverage of Neuronetics at buy
September 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/b-riley-securities-initiates-coverage-of-neuronetics-at-buy/ar-AA2c4hDW
B. Riley Initiates Neuronetics at Buy With $5 Price Target
September 11, 2026  |  marketscreener.comM
See More Neuronetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuronetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuronetics and other key companies, straight to your email.

About Neuronetics

Neuronetics (NASDAQ:STIM) is a medical technology company that develops and commercializes noninvasive treatments for psychiatric and neurological disorders. Its primary product is NeuroStar TMS Therapy, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain associated with mood regulation.

NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for treating major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and depression with anxious distress. The system is designed for use in outpatient physician offices and behavioral health practices, providing an alternative or complement to medication-based treatment.

Founded in 2001 and headquartered in Malvern, Pennsylvania, Neuronetics serves healthcare providers and patients primarily in the United States, with products also available through international distribution relationships. The company has expanded its commercial and clinical presence through its NeuroStar practice network and related patient-support services.

View Neuronetics Profile
Earnings Tools